KINESIS

Kinesis specializes in systems for gait analysis and posturography, which are used to evaluate mobility and balance. Their products include hardware and software solutions like the Kinesis Gait system for analyzing walking patterns, the Kinesis QTUG for timed up-and-go assessments, and the Kinesis Balance application for balance performance testing. These tools are designed for clinical use to help assess patient movement and stability.

Kinesis is headquartered in the United States, which means their devices are subject to FDA regulations. Since their products fall under Class I classification, they are generally considered lower risk but still require compliance with FDA requirements for safety and performance. The U.S. regulatory environment ensures these devices meet necessary standards before entering the market.

Yes, Kinesis devices are listed in the FDA’s Unique Device Identifier (UDI) database. This listing helps ensure traceability and transparency in the medical device supply chain. The UDI system allows healthcare providers, regulators, and manufacturers to track devices throughout their lifecycle, which supports patient safety and regulatory compliance.

Kinesis devices are classified as Class I under FDA regulations, which is the lowest risk category for medical devices. This classification typically applies to devices that pose minimal potential harm to patients, such as gait analysis systems and posturography software. While Class I devices require less stringent premarket review, they still must comply with general controls like good manufacturing practices and labeling requirements to ensure safety and effectiveness.